Phelan-McDermid syndrome

What is Phelan-McDermid syndrome?

Phelan-McDermid syndrome, also known as 22q13 deletion syndrome, is a rare genetic disorder caused by deletions or mutations affecting the SHANK3 gene on chromosome 22. This condition primarily affects neurological development, causing intellectual disability, delayed or absent speech, and autism spectrum behaviors. The syndrome affects both males and females equally and is typically diagnosed in early childhood when developmental delays become apparent. As one of the rarer genetic syndromes, it requires specialized medical care and early intervention to optimize outcomes.

Key statistics

Symptoms

**Primary symptoms:** Neonatal hypotonia, absent or severely delayed speech, intellectual disability, autism spectrum behaviors, developmental delays, seizures, sleep disturbances, feeding difficulties, distinctive facial features.

The symptoms of Phelan-McDermid syndrome typically manifest in infancy and early childhood. Neonatal hypotonia (low muscle tone) is often the first sign, causing babies to appear “floppy” and have difficulty with feeding and motor milestones. Most children experience significant speech delays, with many never developing functional speech or developing only a few words. Intellectual disability ranges from mild to severe, though most individuals fall in the moderate to severe range.

Autism spectrum behaviors are common, including repetitive movements, sensory sensitivities, and challenges with social interaction. Many children engage in self-stimulatory behaviors such as hand-flapping or rocking. Sleep disturbances affect up to 80% of individuals, often involving difficulty falling asleep or frequent night wakings.

Submit Your Paper

Seizures occur in approximately 25-30% of individuals, typically beginning in childhood or adolescence. Feeding difficulties are common in infancy and may persist, sometimes requiring specialized feeding techniques or gastrostomy tubes. Physical features may include a prominent forehead, deep-set eyes, and thick eyebrows, though facial features can be subtle.

Causes and risk factors

Phelan-McDermid syndrome is caused by deletions or mutations affecting the SHANK3 gene located on chromosome 22q13. The SHANK3 gene produces a protein crucial for proper synaptic function in the brain, particularly in areas responsible for learning, memory, and communication. When this gene is deleted or mutated, normal brain development and function are disrupted.

Approximately 90% of cases result from de novo (new) mutations or deletions, meaning they occur spontaneously and are not inherited from parents. The remaining 10% are inherited from a parent who carries a balanced chromosomal rearrangement. Advanced parental age may slightly increase the risk of chromosomal abnormalities, but most cases occur in children born to parents of all ages.

The size of the chromosomal deletion correlates with symptom severity, with larger deletions typically causing more significant developmental challenges. Some individuals have point mutations in the SHANK3 gene rather than deletions, which may result in milder symptoms.

Prevention

As a genetic condition primarily caused by spontaneous mutations, Phelan-McDermid syndrome cannot be prevented through lifestyle modifications or environmental changes. Genetic counseling is recommended for families with a history of the condition, as approximately 10% of cases may be inherited from a parent with a chromosomal rearrangement.

Preconceptional genetic counseling can help identify at-risk couples, and prenatal testing through amniocentesis or chorionic villus sampling can detect 22q13 deletions during pregnancy. Preimplantation genetic testing may be an option for families with known genetic risk factors. While these approaches cannot prevent the condition entirely, they provide families with information to make informed reproductive decisions.

Complications

Without appropriate intervention and support, individuals with Phelan-McDermid syndrome may experience significant lifelong challenges. Untreated seizures can lead to additional cognitive decline and safety risks. Severe feeding difficulties may result in failure to thrive, malnutrition, or aspiration pneumonia.

Communication challenges can lead to behavioral problems, including aggression or self-injury, particularly when individuals cannot express their needs or discomfort. Sleep disturbances can exacerbate behavioral issues and impact family functioning. Some individuals may develop kidney problems, immune system dysfunction, or gastrointestinal issues.

Educational and social isolation may occur without appropriate support services. Many individuals require lifelong care and supervision, though early intervention and ongoing therapies can significantly improve outcomes and quality of life.

Diagnosis

Diagnosis of Phelan-McDermid syndrome requires genetic testing to identify deletions or mutations affecting the SHANK3 gene. Chromosomal microarray analysis is typically the first-line genetic test, as it can detect deletions in the 22q13 region. If microarray results are normal but clinical suspicion remains high, targeted SHANK3 gene sequencing may identify point mutations.

Clinical diagnosis begins with recognition of characteristic symptoms, particularly the combination of neonatal hypotonia, severe speech delays, intellectual disability, and autism spectrum behaviors. Developmental assessments using standardized tools help quantify delays and guide intervention planning.

Additional testing may include electroencephalography (EEG) to evaluate for seizure activity, brain MRI to assess for structural abnormalities, and comprehensive metabolic panels to rule out other causes of developmental delay. Hearing and vision assessments are important, as sensory impairments can compound developmental challenges.

Early genetic testing is crucial, as it enables access to appropriate services and helps families connect with condition-specific resources and support networks.

Treatment

Treatment for Phelan-McDermid syndrome focuses on managing symptoms and maximizing developmental potential through multidisciplinary care. Antiepileptic medications such as levetiracetam, valproic acid, or lamotrigine may be prescribed for seizure management.

Sleep disorders may be treated with melatonin or other sleep aids. Behavioral challenges might require medications such as risperidone or aripiprazole, though these should be used cautiously and with careful monitoring.

Early intervention services including speech therapy, occupational therapy, and physical therapy are essential. Applied behavior analysis (ABA) and other autism-specific interventions can help address behavioral challenges and improve communication skills. Assistive communication devices may benefit non-verbal individuals.

Educational support through individualized education programs (IEPs) helps optimize learning potential. Some individuals may benefit from gastrostomy tube placement for feeding difficulties or specialized orthopedic interventions for musculoskeletal problems.

Currently, there are no approved targeted therapies for Phelan-McDermid syndrome, though several experimental treatments are under investigation.

Prognosis

The prognosis for Phelan-McDermid syndrome varies significantly depending on the size of the genetic deletion and the severity of symptoms. Most individuals have lifelong intellectual disability and require ongoing support, though the degree of independence achievable varies widely.

With early intervention and appropriate support, many individuals can develop functional communication skills, even if verbal speech remains limited. Some learn to walk independently, while others may require mobility aids. Behavioral interventions can help reduce challenging behaviors and improve quality of life.

Life expectancy may be reduced in individuals with severe medical complications, particularly those with intractable seizures or significant feeding difficulties. However, many individuals live well into adulthood with appropriate medical care and support.

The earlier intervention begins, the better the potential outcomes. Families who access comprehensive support services and maintain consistent therapeutic interventions typically see the most improvement in their child’s development and functioning.

Quality of life

Individuals with Phelan-McDermid syndrome can achieve meaningful quality of life with appropriate support and accommodations. Structured daily routines help provide security and predictability. Many individuals enjoy sensory activities, music, and social interaction within their capabilities.

Dietary considerations may include texture modifications or special feeding techniques. Regular exercise and physical activity, adapted to individual abilities, help maintain physical health and can improve mood and behavior. Swimming, walking, and therapeutic horseback riding are often beneficial activities.

Sleep hygiene is particularly important, as sleep disturbances are common. Consistent bedtime routines, comfortable sleep environments, and sometimes medication can improve sleep quality for both individuals and their families.

Educational and vocational programs designed for individuals with developmental disabilities can provide meaningful activities and social interaction. Some individuals may participate in supported employment or volunteer activities that match their interests and abilities.

Pregnancy and fertility

Most women with Phelan-McDermid syndrome have normal reproductive anatomy, though cognitive and physical disabilities may affect their ability to understand and manage reproductive health. Fertility decisions should involve careful consideration of the individual’s capacity to understand pregnancy and parenting responsibilities.

For parents with Phelan-McDermid syndrome, genetic counseling is essential, as there is a 50% chance of passing the condition to offspring if the deletion is inherited rather than de novo. Prenatal care requires coordination with specialists familiar with developmental disabilities.

Medication management during pregnancy requires careful review, as some seizure medications and psychiatric medications may pose risks to developing babies. Women of childbearing age should take folic acid supplementation as recommended for all women of reproductive age.

Children

Children with Phelan-McDermid syndrome benefit from early identification and intervention. Parents should work closely with pediatric specialists, including developmental pediatricians, neurologists, and geneticists, to create comprehensive care plans.

Educational planning should begin early, with focus on developing individualized education programs that address communication, behavioral, and academic needs. Alternative communication methods, including picture exchange systems or electronic devices, may be crucial for non-verbal children.

Behavioral support plans help address challenging behaviors while building positive skills. Social skills training and peer interaction opportunities, when appropriately supported, can enhance development and quality of life.

Regular medical monitoring is important to identify and address complications such as seizures, feeding difficulties, or sleep problems as they arise.

When to see a doctor

Immediate medical attention is needed for seizures lasting more than five minutes, signs of dehydration or malnutrition, severe behavioral changes that pose safety risks, or any signs of illness in non-verbal individuals who cannot communicate symptoms.

Routine medical care should include regular monitoring by specialists familiar with Phelan-McDermid syndrome, annual developmental assessments, and ongoing evaluation of therapeutic interventions. Changes in behavior, development, or medical status warrant prompt evaluation.

Parents should maintain regular contact with their medical team and seek guidance when new challenges arise or when considering changes to treatment plans.

Regional context

Limited data exists specifically regarding Phelan-McDermid syndrome prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean areas. The condition’s rarity means that regional genetic studies often have insufficient sample sizes to determine population-specific prevalence rates.

We invite medical professionals and researchers from these regions to contribute their experiences and data to help build understanding of Phelan-McDermid syndrome’s presentation and prevalence in diverse populations. Such contributions would be valuable additions to the global medical knowledge base and could help improve care for affected families in these regions.

Research and clinical trials

Current research focuses on developing targeted therapies that address the underlying SHANK3 protein deficiency. Several approaches are being investigated, including gene therapy, small molecule drugs that enhance SHANK3 function, and treatments that target downstream effects of SHANK3 deficiency.

IGF-1 (insulin-like growth factor-1) has shown promise in preclinical studies and small human trials for improving synaptic function and communication abilities. Other research focuses on understanding the specific mechanisms by which SHANK3 deficiency affects brain development and function.

Clinical trials for Phelan-McDermid syndrome can be found through ClinicalTrials.gov using search terms “Phelan McDermid” or “22q13 deletion.” The Phelan-McDermid Syndrome Foundation maintains updated information about ongoing research opportunities and helps connect families with appropriate studies.

Biomarker research aims to develop better tools for measuring treatment response and disease progression, which could accelerate the development of effective therapies.

Frequently asked questions

Will my child with Phelan-McDermid syndrome ever talk?

While most children with Phelan-McDermid syndrome have significant speech delays, some do develop functional communication. Even non-verbal children can often learn to communicate through alternative methods like picture systems or electronic devices. Early and intensive speech therapy provides the best opportunity for communication development.

Is Phelan-McDermid syndrome inherited from parents?

Approximately 90% of cases are de novo (new mutations), meaning they are not inherited from parents. About 10% are inherited from a parent who carries a chromosomal rearrangement. Genetic counseling can help determine the specific cause and recurrence risk for each family.

What is the life expectancy for someone with Phelan-McDermid syndrome?

Life expectancy varies depending on the severity of symptoms and associated medical complications. Many individuals live well into adulthood with appropriate medical care, though some may have shortened lifespans due to seizures, feeding difficulties, or other medical issues.

Can treatments cure Phelan-McDermid syndrome?

Currently, there is no cure for Phelan-McDermid syndrome. Treatment focuses on managing symptoms and maximizing developmental potential through therapies, education, and medical management. Research into targeted therapies is ongoing and offers hope for future treatments.

How can I find other families affected by Phelan-McDermid syndrome?

The Phelan-McDermid Syndrome Foundation connects families worldwide and provides resources, support groups, and information about the condition. Many families find tremendous value in connecting with others who understand their experiences and challenges.

Support and resources

International organizations:
– Phelan-McDermid Syndrome Foundation: https://pmsf.org
– Orphanet (Rare Disease Database): https://www.orpha.net
– National Organization for Rare Disorders (NORD): https://rarediseases.org
– EURORDIS (European Rare Disease Organization): https://www.eurordis.org
– Global Genes: https://globalgenes.org

Research and medical information:
– GeneReviews (NCBI): https://www.ncbi.nlm.nih.gov/books/NBK1198/
– ClinicalTrials.gov: https://clinicaltrials.gov

General autism and developmental disability resources:
– Autism Speaks: https://www.autismspeaks.org
– The Arc: https://thearc.org

Related conditions

Autism Spectrum Disorder
Angelman Syndrome
Prader-Willi Syndrome
Rett Syndrome
Fragile X Syndrome

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.